Recently, it has been reported that PD patients, carrying the most frequent mutation in LRRK2 with the substitution Gly‐Ser in 2019 position, show severe deficits in the expression of glutamate transporter EAAT2 (Iovino et al., 2022). Here, SLC1A2 is linked to Parkinson disease.